- Business Wire•18 hours agoARIAD Completes Rolling Submission of New Drug Application for Brigatinib to the U.S. Food and Drug Administration
ARIAD Pharmaceuticals, Inc. today announced it has completed the rolling submission of the New Drug Application for its investigational anaplastic lymphoma kinase inhibitor, brigatinib, to the U.S.
- Business Wire•2 days ago
ARIAD Pharmaceuticals, Inc. today announced that it will present at the Morgan Stanley Global Healthcare Conference being held in New York City. Paris Panayiotopoulos, president and chief executive officer, will provide an overview of the Company’s business on Monday, September 12, 2016 at 2:50 p.m.
- Capital Cube•7 days ago
Categories: ETFs Yahoo Finance Click here to see latest analysis ETF’s with exposure to ARIAD Pharmaceuticals, Inc. Here are 5 ETF’s with the largest exposure to ARIA-US. Comparing the performance and risk of ARIAD Pharmaceuticals, Inc. with the ETF’s that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
Ariad Pharmaceuticals Inc. (ARIA)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||10.14 x 200|
|Day's Range||10.27 - 10.45|
|52wk Range||4.37 - 10.85|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-33.43|
|Avg Vol (3m)||5,028,495|
|Dividend & Yield||N/A (N/A)|